160 related articles for article (PubMed ID: 26940993)
1. RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.
Passariello CL; Martinez EC; Thakur H; Cesareo M; Li J; Kapiloff MS
J Mol Cell Cardiol; 2016 Apr; 93():98-105. PubMed ID: 26940993
[TBL] [Abstract][Full Text] [Related]
2. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.
Wu X; Simpson J; Hong JH; Kim KH; Thavarajah NK; Backx PH; Neel BG; Araki T
J Clin Invest; 2011 Mar; 121(3):1009-25. PubMed ID: 21339642
[TBL] [Abstract][Full Text] [Related]
3. Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome.
Yin JC; Platt MJ; Tian X; Wu X; Backx PH; Simpson JA; Araki T; Neel BG
Nat Commun; 2017 May; 8():15518. PubMed ID: 28548091
[TBL] [Abstract][Full Text] [Related]
4. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.
Dhandapany PS; Fabris F; Tonk R; Illaste A; Karakikes I; Sorourian M; Sheng J; Hajjar RJ; Tartaglia M; Sobie EA; Lebeche D; Gelb BD
J Mol Cell Cardiol; 2011 Jul; 51(1):4-15. PubMed ID: 21440552
[TBL] [Abstract][Full Text] [Related]
6. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants.
Wu X; Yin J; Simpson J; Kim KH; Gu S; Hong JH; Bayliss P; Backx PH; Neel BG; Araki T
Mol Cell Biol; 2012 Oct; 32(19):3872-90. PubMed ID: 22826437
[TBL] [Abstract][Full Text] [Related]
7. Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy.
Li J; Kritzer MD; Michel JJ; Le A; Thakur H; Gayanilo M; Passariello CL; Negro A; Danial JB; Oskouei B; Sanders M; Hare JM; Hanauer A; Dodge-Kafka K; Kapiloff MS
Circ Res; 2013 Jan; 112(1):128-39. PubMed ID: 22997248
[TBL] [Abstract][Full Text] [Related]
8. p90 ribosomal S6 kinase 3 contributes to cardiac insufficiency in α-tropomyosin Glu180Gly transgenic mice.
Passariello CL; Gayanilo M; Kritzer MD; Thakur H; Cozacov Z; Rusconi F; Wieczorek D; Sanders M; Li J; Kapiloff MS
Am J Physiol Heart Circ Physiol; 2013 Oct; 305(7):H1010-9. PubMed ID: 23913705
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Pandit B; Sarkozy A; Pennacchio LA; Carta C; Oishi K; Martinelli S; Pogna EA; Schackwitz W; Ustaszewska A; Landstrom A; Bos JM; Ommen SR; Esposito G; Lepri F; Faul C; Mundel P; López Siguero JP; Tenconi R; Selicorni A; Rossi C; Mazzanti L; Torrente I; Marino B; Digilio MC; Zampino G; Ackerman MJ; Dallapiccola B; Tartaglia M; Gelb BD
Nat Genet; 2007 Aug; 39(8):1007-12. PubMed ID: 17603483
[TBL] [Abstract][Full Text] [Related]
10. Is Raf1 a nexus for cardiac hypertrophic signaling in human disease?
Del Re DP; Sadoshima J
J Mol Cell Cardiol; 2011 Jul; 51(1):1-3. PubMed ID: 21539844
[No Abstract] [Full Text] [Related]
11. A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation.
Jaouadi H; Chehida AB; Kraoua L; Etchevers HC; Argiro L; Kasdallah N; Blibech S; Delague V; Lévy N; Tebib N; Mrad R; Abdelhak S; Benkhalifa R; Zaffran S
Genet Res (Camb); 2019 Apr; 101():e6. PubMed ID: 31030682
[TBL] [Abstract][Full Text] [Related]
12. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.
Harms FL; Alawi M; Amor DJ; Tan TY; Cuturilo G; Lissewski C; Brinkmann J; Schanze D; Kutsche K; Zenker M
Am J Med Genet A; 2018 Feb; 176(2):470-476. PubMed ID: 29271604
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular evidence for the impact of a hypertrophic cardiomyopathy-associated RAF1 variant on the structure and function of contractile machinery in bioartificial cardiac tissues.
Nakhaei-Rad S; Haghighi F; Bazgir F; Dahlmann J; Busley AV; Buchholzer M; Kleemann K; Schänzer A; Borchardt A; Hahn A; Kötter S; Schanze D; Anand R; Funk F; Kronenbitter AV; Scheller J; Piekorz RP; Reichert AS; Volleth M; Wolf MJ; Cirstea IC; Gelb BD; Tartaglia M; Schmitt JP; Krüger M; Kutschka I; Cyganek L; Zenker M; Kensah G; Ahmadian MR
Commun Biol; 2023 Jun; 6(1):657. PubMed ID: 37344639
[TBL] [Abstract][Full Text] [Related]
14. RSK3: A regulator of pathological cardiac remodeling.
Martinez EC; Passariello CL; Li J; Matheson CJ; Dodge-Kafka K; Reigan P; Kapiloff MS
IUBMB Life; 2015 May; 67(5):331-7. PubMed ID: 25988524
[TBL] [Abstract][Full Text] [Related]
15. RAF1 mutation leading to hypertrophic cardiomyopathy in a Chinese family with a history of sudden cardiac death: A diagnostic insight into Noonan syndrome.
Zheng J; Peng L; Cheng R; Li Z; Xie J; Huang E; Cheng J; Zhao Q
Mol Genet Genomic Med; 2024 Jan; 12(1):e2290. PubMed ID: 37787490
[TBL] [Abstract][Full Text] [Related]
16. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.
Kobayashi T; Aoki Y; Niihori T; Cavé H; Verloes A; Okamoto N; Kawame H; Fujiwara I; Takada F; Ohata T; Sakazume S; Ando T; Nakagawa N; Lapunzina P; Meneses AG; Gillessen-Kaesbach G; Wieczorek D; Kurosawa K; Mizuno S; Ohashi H; David A; Philip N; Guliyeva A; Narumi Y; Kure S; Tsuchiya S; Matsubara Y
Hum Mutat; 2010 Mar; 31(3):284-94. PubMed ID: 20052757
[TBL] [Abstract][Full Text] [Related]
17. Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
Razzaque MA; Nishizawa T; Komoike Y; Yagi H; Furutani M; Amo R; Kamisago M; Momma K; Katayama H; Nakagawa M; Fujiwara Y; Matsushima M; Mizuno K; Tokuyama M; Hirota H; Muneuchi J; Higashinakagawa T; Matsuoka R
Nat Genet; 2007 Aug; 39(8):1013-7. PubMed ID: 17603482
[TBL] [Abstract][Full Text] [Related]
18. Neonatal pulmonary arterial hypertension and Noonan syndrome: two fatal cases with a specific RAF1 mutation.
Hopper RK; Feinstein JA; Manning MA; Benitz W; Hudgins L
Am J Med Genet A; 2015 Apr; 167A(4):882-5. PubMed ID: 25706034
[TBL] [Abstract][Full Text] [Related]
19. New Noonan syndrome model mice with RIT1 mutation exhibit cardiac hypertrophy and susceptibility to β-adrenergic stimulation-induced cardiac fibrosis.
Takahara S; Inoue SI; Miyagawa-Tomita S; Matsuura K; Nakashima Y; Niihori T; Matsubara Y; Saiki Y; Aoki Y
EBioMedicine; 2019 Apr; 42():43-53. PubMed ID: 30898653
[TBL] [Abstract][Full Text] [Related]
20. MEK Inhibition in a Newborn with
Mussa A; Carli D; Giorgio E; Villar AM; Cardaropoli S; Carbonara C; Campagnoli MF; Galletto P; Palumbo M; Olivieri S; Isella C; Andelfinger G; Tartaglia M; Botta G; Brusco A; Medico E; Ferrero GB
Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
